Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three active MDMA-assisted sessions.
As of July 19, 2022, one subject completed the trial. Two additional subjects have been treated, and four subjects are enrolled into this study.
